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S U M M A R Y
Background: Crimean-Congo hemorrhagic fever (CCHF) is characterized by vascular dysfunction,
indicating the involvement of endothelial cells. C-type natriuretic peptide (CNP) plays a critical role
in the coordination of vascular tone and is associated with the prognosis in critically ill patients such as
those with sepsis and septic shock. We investigated whether CNP is related to the severity of CCHF.
Methods: Forty-eight consecutive patients with a laboratory conﬁrmed diagnosis of CCHF and 40 age–
sex-matched healthy volunteers as the control group were prospectively enrolled into the study. CCHF
patients were classiﬁed according to the disease severity into a non-severe group (n = 28) and a severe
group (n = 20).
Results: The CNP levels were detected to be 0.43 (0.4–0.7) ng/ml in the control group, 0.87 (0.7–1.0) ng/
ml in the non-severe CCFH group, and 1.27 (0.8–1.7) ng/ml in the severe CCHF group. According to the
receiver operating characteristics curve analysis, the optimal cut-off value of CNP to predict disease
severity was >1.22 ng/ml, with 89.3% speciﬁcity and 55% sensitivity. CNP >1.22 ng/ml, lactate
dehydrogenase >480 IU/l, and aspartate aminotransferase >202 IU/l were found to have prognostic
signiﬁcance in the univariate analysis. In the multivariate logistic regression analysis by forward
stepwise method, CNP >1.22 ng/ml (odds ratio 8.336, p = 0.016) and lactate dehydrogenase >480 IU/l
(odds ratio 16.206, p = 0.002) remained associated with disease severity after adjustment for
confounding variables.
Conclusions: CNP measurement could help in the risk stratiﬁcation of patients with CCHF.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Crimean-Congo hemorrhagic fever (CCHF) is a zoonotic viral
disease caused by a tick-borne virus of the genus Nairovirus.1 CCHF
has a fatality rate of 3–30% of cases,2 and the pathogenesis of the
disease is not well understood. Endothelial damage has an
important role in the pathogenesis of CCHF.3 In severe cases,
death occurs as a result of disseminated intravascular coagulation,
multiorgan failure, and circulatory shock. Systemic inﬂammatory
reactions occur during hemorrhagic manifestations.4,5
C-type natriuretic peptide (CNP) is a member of the family of
natriuretic peptides.6 It is mostly produced by endothelial cells,7
and it plays a critical role in the coordination of vascular tone.8 CNP
release in response to proinﬂammatory cytokines suggests an
interaction of macrophageal cytokine synthesis and vascular* Corresponding author. Tel.: +90 506 4183409; fax: +90 346 2191268.
E-mail address: dralizorlu@gmail.com (A. Zorlu).
1201-9712/$36.00 – see front matter  2012 International Society for Infectious Disea
http://dx.doi.org/10.1016/j.ijid.2012.04.009endothelium.9 Recent studies have found that CNP and the N-
terminal pro-peptide of CNP (NT-proCNP) are increased in
critically ill patients such as those with sepsis and septic shock.10,11
The potential use of CNP in the risk stratiﬁcation of patients
with CCHF has not been previously studied. We investigated
whether CNP is related to the severity of CCHF.
2. Methods
Forty-eight consecutive patients with a laboratory conﬁrmed
diagnosis of CCHF and 40 age–sex-matched healthy volunteers as
the control group were prospectively enrolled in the study at
Cumhuriyet University School of Medicine between January and
October 2011. Informed consent was obtained from all study
participants. The diagnosis of CCHF was conﬁrmed by positive
qualitative PCR test in the Virology Laboratory of the Reﬁk Saydam
National Hygiene Center of the Turkish Ministry of Health. The
TaqMan-based one-step reverse transcriptase PCR assay was used
to detect CCHF viral RNA.12ses. Published by Elsevier Ltd. All rights reserved.
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based on disease severity (severe (n = 20) and non-severe (n = 28)),
as previously reported by Cevik et al.13 Patients with at least one of
the following were considered severe cases: somnolence, melena,
activated partial thromboplastin time (APTT) 60 s, and thrombo-
cyte count 20  109 cells/l. Data collected, per protocol, included
age, gender, duration of symptoms, history of hypertension,
diabetes mellitus, and smoking, admission CNP, biochemical and
coagulation parameters, and complete blood count. Of note, only
admission parameters were considered in this study (ﬁrst ever
obtained parameter, within 15 min of admission). History of
hypertension was deﬁned as a previous blood pressure >140/
90 mmHg on more than two occasions during ofﬁce measure-
ments, or having received antihypertensive treatment. Diabetes
mellitus was deﬁned as a previous fasting blood glucose 126 mg/
dl, or having received antidiabetic treatment.
Blood sampling was performed as soon as a venous and/or
arterial line was placed in all patients. The 10-ml blood samples
were centrifuged in gel-containing vacuumed biochemistry tubes
at 400 rpm for 4 min and the serum was stored in Eppendorf tubes
at 23 8C. Serum CNP levels were measured by CNP-22 (human,
rat, mouse, porcine) enzyme immunoassay (EIA) kit, based on
standard sandwich ELISA technology.
2.1. Statistical analysis
Continuous variables were expressed as the mean  standard
deviation, or median (interquartile range) in the presence of an
abnormal distribution, and categorical variables as percentages.
SPSS 14.0 (SPSS, Inc., Chicago, IL, USA) was used to perform the
statistical procedures. Receiver operating characteristic (ROC) curve
analysis was performed to identify the optimal cut-off point of CNP,
lactate dehydrogenase (LDH), and aspartate aminotransferase (AST)
(at which sensitivity and speciﬁcity would be maximal) for the
prediction of disease severity. Areas under the curve (AUC) were
calculated as measures of the accuracy of the tests. We compared the
AUC with the use of the Z-test. Comparisons between groups were
performed using one-way analysis of variance (ANOVA) with
post-hoc analysis by Tukey’s HSD, or an independent samples t-test,Table 1
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partial thromboplastin time; INR, international normalized ratio; WBC, white blood cell.and the Kruskal–Wallis test or Mann–Whitney U-test for normally and
non-normally distributed data, respectively. Categorical variables were
analyzed between groups using the Chi-square test. We used univariate
analysis to quantify the association of variables with disease severity.
Variables found to be statistically signiﬁcant in the univariate analysis,
as well as potential confounders (age, gender, and duration of
symptoms), were used in a multivariate logistic regression model
with forward stepwise method in order to determine the independent
prognostic factors of disease severity. A p-value of 0.05 was considered
statistically signiﬁcant.
3. Results
The CNP levels were detected to be 0.43 (0.4–0.7) ng/ml in the
control group, 0.87 (0.7–1.0) ng/ml in the non-severe CCHF group,
and 1.27 (0.8–1.7) ng/ml in the severe CCHF group. CNP levels were
observed to be signiﬁcantly higher in patients with severe CCHF
compared to those with non-severe CCHF and the control group (p
= 0.007 and p < 0.001, respectively). In addition, those with non-
severe CCHF were also found to have a signiﬁcantly higher CNP
level relative to the control group (p < 0.001) (Table 1, Figure 1).
A comparison of the baseline characteristics of patients in the
non-severe and severe CCHF groups is presented in Table 1. Serum
levels of AST and LDH were signiﬁcantly higher in the severe cases
than in the non-severe cases. There was no signiﬁcant difference
between the two groups in terms of other clinical and laboratory
parameters (Table 1).
According to the ROC curve analysis, the optimal cut-off value of
CNP to predict disease severity was >1.22 ng/ml, with 89.3%
speciﬁcity and 55% sensitivity (AUC 0.732, 95% conﬁdence interval
0.585–0.850; Figure 2). In addition, the optimal cut-off value of
LDH to predict disease severity was >480 IU/l, with 85% sensitivity
and 67.9% speciﬁcity, and of AST was >202 IU/l, with 70%
sensitivity and 75% speciﬁcity.
Results of the univariate and multivariate logistic regression
analyses for the prediction of severe CCHF are listed in Table 2. CNP
>1.22 ng/ml, LDH >480 IU/l, and AST >202 IU/l were found to have
prognostic signiﬁcance. In the multivariate logistic regression
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15/13 12/8 0.650
6 (21%) 8 (40%) 0.165
4 (14%) 3 (15%) 1.000
7 (25%) 9 (45%) 0.148
2.4  1.3 2.8  1.9 0.436
17  7 17.4  10 0.859
0.9  0.2 1.07  0.8 0.891
62 (32–111) 73 (37–109) 0.565
149 (69–211) 251 (139–381) 0.011
390 (306–577) 1004 (512–1574) <0.001
13.5  3 13.8  3.7 0.721
40 (37–52) 62 (55–89) <0.001
1.2  0.2 1.3  0.3 0.639
3.1  2.9 3.6  2.9 0.573
14.1  1.7 14.4  2.1 0.624
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sferase; AST, aspartate aminotransferase; LDH, lactate dehydrogenase; APTT, activated
Figure 2. ROC curve analysis for C-type natriuretic peptide (AUC 0.732, 95% CI 0.585–0.850) and lactate dehydrogenase (AUC 0.809, 95% CI 0.670–0.908).
Figure 1. Comparison of C-type natriuretic peptide levels (median (interquartile range)) between the three groups.
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the development of severe CCHF after adjustment for other
potential confounders (age, gender, and duration of symptoms)
and variables found to be statistically signiﬁcant in the univariate
analysis (Table 2).
4. Discussion
To the best of our knowledge, this study is the ﬁrst in the
published literature to investigate the predictive value of admission
CNP levels on the severity of CCHF. We found that CNP was
signiﬁcantly increased in CCHF patients. Furthermore, even after
controlling for confounding parameters, we found that higher CNP
levels were strongly associated with disease severity.
Previous studies have reported that decreased levels of
thrombocytes and ﬁbrinogen, and increased levels of white bloodcells, AST, alanine aminotransferase (ALT), creatine kinase, LDH,
and soluble urokinase plasminogen activator receptor, as well as a
prolonged APTT, are associated with a poor outcome in CCHF
patients.3,14–16 Ozturk et al. and Bodur et al. have shown that the
level of hyaluronic acid, sICAM-1 (soluble intercellular adhesion
molecule 1), sVCAM-1 (soluble vascular cell adhesion molecule 1),
and VEGF-A (vascular endothelial growth factor A) can be used as a
prognostic marker in CCHF.17,18 Furthermore, the severe form of
CCHF is characterized by hemorrhage, disseminated intravascular
coagulation, vascular dysfunction, and shock.15,19
Recent studies have shown that serum CNP and NT-proCNP levels
are increased in sepsis, septic shock, and any critically ill patients,
conditions characterized by inadequate tissue perfusion.10,11,20
Vlachopoulos et al. found that NT-proCNP is associated with arterial
stiffness, endothelial function, and early atherosclerosis.21 In a
global arterial approach, their study demonstrated a relationship
Table 2
Univariate and multivariate analyses of severe CCHF
Univariate analysis Multivariate analysisa
p-Value OR 95% CI p-Value OR 95% CI
C-type natriuretic peptide >1.22 ng/ml 0.010 5.622 1.520–20.799 0.016 8.336 1.495–46.496
LDH >480 IU/l 0.001 11.963 2.775–51.580 0.002 16.206 2.871–91.477
AST >202 IU/l 0.003 7.000 1.940–25.255
Age (years) 0.320 1.032 0.970–1.099
Gender 0.658 0.769 0.240–2.460
Duration of symptoms (days) 1.157 0.429 0.806–1.662
Hypertension 0.168 2.444 0.686–8.712
Diabetes mellitus 0.945 1.059 0.209–5.534
Smoking 0.152 2.455 0.719–8.380
BUN (mg/dl) 0.855 1.006 0.940–1.077
Creatinine (mg/dl) 0.366 1.821 0.497–6.675
ALT (IU/l) 0.339 1.003 0.997–1.010
Prothrombin time (s) 0.714 1.033 0.867–1.232
INR 0.631 1.657 0.211–13.003
WBC ( 109 cells/l) 0.567 1.060 0.867–1.296
Hemoglobin (g/dl) 0.616 1.085 0.788–1.495
CCHF, Crimean-Congo hemorrhagic fever; OR, odds ratio; 95% CI, 95% conﬁdence interval; LDH, lactate dehydrogenase; AST, aspartate aminotransferase; BUN, blood urea
nitrogen; ALT, alanine aminotransferase; INR, international normalized ratio; WBC, white blood cell.
a C-type natriuretic peptide >1.22 ng/ml, LDH >480 IU/l, AST >202 IU/l, age, gender, and duration of symptoms were entered into the multivariate logistic regression model.
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changes.
The speciﬁc mechanisms underlying the pathogenesis of CCHF
infection have not been clearly explained. Endothelial cells and
mononuclear phagocytes are major targets for the CCHF virus.22 In
particular, infection of the endothelium has an important role in
the pathogenesis of CCHF. Endothelial damage contributes to
hemostatic failure by stimulating platelet aggregation and
degranulation, with consequent activation of the intrinsic coagu-
lation cascade.23,24 Furthermore, it is probable that the endotheli-
um plays a role in the pathogenesis of CCHF through the secretion
of cytokines and other inﬂammatory mediators.22 Recent studies
have demonstrated that serum levels of tumor necrosis factor-
alpha, interleukin-1, and interleukin-6 are higher in fatal than non-
fatal CCHF cases.25,26 On the other hand, in CCHF patients, toll-like
receptors can potentially be related to the natural course and/or
severity of the disease, as described in a recent paper.27 As a result
of this pathophysiological pathway, it appears that CNP is released
from the damaged endothelium in association with the severity of
disease.
Our study ﬁndings of higher ALT, AST, and LDH levels in patients
with more severe disease are in accordance with those of previous
studies.3,14,15 However, only LDH levels along with CNP were
identiﬁed as independent predictors for the severity of the disease.
There are some limitations of the current study. First this was a
single-center study and it represents data from a tertiary care
center. Furthermore, viral load measurements would have
provided more insight with regard to the level of CNP. However,
the central laboratory does not provide quantitative results with
the conﬁrmation of CCHF in our country.
Increased levels of CNP, one of the most important indicators of
endothelial function, is not surprising in CCHF, which is character-
ized by endothelial damage. Within the light of our study, we think
that low CNP levels could potentially identify those with mild
progression of the disease. In addition, we believe that the
evaluation of CNP levels could be helpful for the selection of
patients for aggressive treatment and intensive care unit admission.
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